$ATXI News

Avenue Therapeutics Q1 EPS $(0.21) Up From $(0.62) YoY

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Avenue Therapeutics Q2 EPS $0.11 Up From $(6.43) YoY, Sales $1.404M

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Avenue Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Allarity appoints Alex Epshinsky as CFO

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics: A Strong Buy on Promising AJ201 Developments and Strategic Initiatives

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024

Avenue Therapeutics Stockholders Approve Key Proposals

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group